Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GILD

Gilead Sciences, Inc

Dec 24 • 04:00PM ET

93.95

Dollar change +0.55
Percentage change 0.59	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB COWZ VYM

Scroll to Statements

Index	NDX, S&P 500	P/E	1059.19	EPS (ttm)	0.09	Insider Own	0.10%	Shs Outstand	1.25B	Perf Week	1.24%
Market Cap	117.09B	Forward P/E	12.41	EPS next Y	7.57	Insider Trans	-29.65%	Shs Float	1.24B	Perf Month	4.17%
Income	126.00M	PEG	113.19	EPS next Q	1.72	Inst Own	85.34%	Short Float	1.77%	Perf Quarter	14.28%
Sales	28.27B	P/S	4.14	EPS this Y	-34.72%	Inst Trans	0.47%	Short Ratio	3.34	Perf Half Y	35.55%
Book/sh	14.83	P/B	6.34	EPS next Y	72.59%	ROA	0.22%	Short Interest	21.98M	Perf Year	17.94%
Cash/sh	5.37	P/C	17.48	EPS next 5Y	9.36%	ROE	0.62%	52W Range	62.07 - 98.90	Perf YTD	15.97%
Dividend Est.	3.06 (3.26%)	P/FCF	12.42	EPS past 5Y	1.55%	ROI	0.32%	52W High	-5.01%	Beta	0.20
Dividend TTM	3.08 (3.28%)	Quick Ratio	1.10	Sales past 5Y	4.16%	Gross Margin	77.96%	52W Low	51.36%	ATR (14)	2.05
Dividend Ex-Date	Dec 13, 2024	Current Ratio	1.26	EPS Y/Y TTM	-97.87%	Oper. Margin	37.45%	RSI (14)	58.92	Volatility	2.28% 2.22%
Employees	18000	Debt/Eq	1.26	Sales Y/Y TTM	3.72%	Profit Margin	0.45%	Recom	1.97	Target Price	99.21
Option/Short	Yes / Yes	LT Debt/Eq	1.16	EPS Q/Q	-42.06%	Payout	66.62%	Rel Volume	0.32	Prev Close	93.40
Sales Surprise	7.55%	EPS Surprise	32.03%	Sales Q/Q	7.05%	Earnings	Nov 06 AMC	Avg Volume	6.57M	Price	93.95
SMA20	1.79%	SMA50	3.44%	SMA200	21.75%	Trades		Volume	2,109,120	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87
Dec-13-22	Resumed	BofA Securities	Neutral	$85
Dec-09-22	Downgrade	DZ Bank	Buy → Hold	$90

Show Previous Ratings

Dec-25-24 11:30AM	Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock (Benzinga)
Dec-23-24 03:25PM	Gilead Sciences Stock Today: Boost Your Return With This Covered Call Trade (Investor's Business Daily)
08:44AM	Gilead Sciences (GILD) Made Big Announcements in Q3 (Insider Monkey)
08:00AM	How To Invest: The Slow Saucer Base Can Produce Quick Returns (Investor's Business Daily)
Dec-20-24 04:05PM	Gilead Sciences to Present at Upcoming Investor Conference (Business Wire)
06:00PM	Loading…
Dec-19-24 06:00PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know (Zacks)
Dec-18-24 07:20AM	Gilead, Terray Therapeutics announce research collaboration (TipRanks)
06:58AM	Gilead and Terray link to develop small-molecule therapies (Pharmaceutical Technology)
Dec-17-24 08:30AM	U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Business Wire)
07:00AM	Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies (Business Wire)
Dec-16-24 12:00PM	Gilead (GILD) Upgraded to Buy: Here's Why (Zacks)
Dec-13-24 05:50PM	Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know (Zacks)
12:15PM	Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report (Benzinga)
06:37AM	Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis (Business Wire)
Dec-12-24 05:54PM	Gilead appoints Sanofi official Dietmar Berger as next chief medical officer (Reuters)
05:30PM	Loading…
05:30PM	Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer (Business Wire)
01:13PM	Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing (Benzinga)
09:40AM	Is Gilead Sciences (GILD) Stock Undervalued Right Now? (Zacks)
09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:00AM	Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers (Benzinga)
Dec-09-24 05:45PM	Kite's Yescarta Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 (Business Wire)
04:30PM	Longest Follow-Up Data Reported for Kite's Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits (Business Wire)
04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
Dec-08-24 12:30PM	Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH (Business Wire)
Dec-05-24 04:00AM	Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying. (Barrons.com)
Dec-03-24 09:30AM	Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
07:00AM	Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target (Business Wire)
Dec-02-24 07:45AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
Nov-28-24 05:05PM	Gilead announces PURPOSE 2 trial data published in NEJM (TipRanks)
09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
07:07AM	Loading…
07:07AM	Gileads twice-yearly lenacapavir shows promise in HIV prevention trial (Clinical Trials Arena)
Nov-27-24 05:00PM	Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results (Business Wire)
Nov-26-24 09:40AM	Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic (ACCESSWIRE)
07:43AM	Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech (Pharmaceutical Technology)
Nov-22-24 06:35AM	Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program (TipRanks)
Nov-18-24 09:47AM	Gileads Livdelzi shows promise in PBC clinical trial (Clinical Trials Arena)
12:42AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
Nov-15-24 02:14PM	Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease (Benzinga)
11:00AM	Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis (Business Wire)
Nov-14-24 09:54AM	Citi initiates coverage on 5 new biotech stocks (Investing.com)
09:30AM	Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet (Zacks)
09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Nov-13-24 08:24PM	Gilead Prices $3.5 Billion of Senior Unsecured Notes (Business Wire)
06:45AM	Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow (Business Wire)
12:04AM	Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight (GuruFocus.com)
Nov-12-24 05:30AM	Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline (Business Wire)
Nov-10-24 09:30AM	3 Spectacular High-Yield Dividend Stocks to Buy in November (Motley Fool)
Nov-08-24 04:05PM	Gilead Sciences to Present at Upcoming Investor Engagements (Business Wire)
09:34AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
Nov-07-24 04:04PM	Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise (Investor's Business Daily) +6.77%
01:46PM	HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook (Benzinga)
12:57PM	Gilead increases 2024 outlook, expects new drug filing by end of year (Yahoo Finance)
10:01AM	Q3 2024 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
09:34AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
08:30AM	Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic (Business Wire)
02:20AM	Gilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales ... (GuruFocus.com)
Nov-06-24 09:00PM	Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates (Zacks)
04:52PM	Gilead Sciences Rides Covid Treatment To Another Beat And Raise (Investor's Business Daily)
04:19PM	Gilead 3rd-quarter results beat Wall Street estimates, raises outlook (Reuters)
04:13PM	Gilead: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Gilead Sciences Announces Third Quarter 2024 Financial Results (Business Wire)
04:01PM	Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales (Investor's Business Daily)
12:26PM	Top 20 biopharmas market cap rises 2% in Q3 2024 amid flurry of drug approvals (Pharmaceutical Technology)
Nov-05-24 07:19PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
09:15AM	Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World (Business Wire)
Nov-04-24 05:53PM	Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now? (Insider Monkey)
Nov-03-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
Nov-01-24 09:15AM	Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Oct-31-24 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know (Zacks)
09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:00AM	AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies (ACCESSWIRE)
Oct-30-24 10:01AM	Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline (Zacks)
Oct-29-24 06:00PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why (Zacks)
Oct-24-24 08:15AM	3 Absurdly Cheap Stocks That Pay High Dividends (Motley Fool)
Oct-23-24 06:00PM	Why Gilead Sciences (GILD) Dipped More Than Broader Market Today (Zacks)
Oct-22-24 12:36PM	Gilead and MSD to advance once-weekly HIV treatment to Phase III (Clinical Trials Arena)
09:00AM	Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024 (Business Wire)
Oct-21-24 12:28PM	Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks (Benzinga)
Oct-19-24 05:09PM	Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 (Business Wire)
11:57AM	Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE (Insider Monkey)
Oct-18-24 02:34PM	After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment (Benzinga)
08:50AM	Gilead withdraws bladder cancer drug in US after failed trial (Reuters)
Oct-17-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Oct-15-24 06:00PM	Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts (Zacks)
Oct-14-24 10:01AM	How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket (Benzinga)
Oct-10-24 07:22PM	Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs? (Insider Monkey)
Oct-09-24 05:52PM	Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ... (GuruFocus.com)
04:05PM	Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024 (Business Wire)
08:30AM	Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024 (Business Wire)
Oct-08-24 06:00PM	Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
09:25AM	Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic (ACCESSWIRE)
Oct-07-24 11:00AM	Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference (Business Wire)
02:52AM	AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history (Pharmaceutical Technology)
Oct-03-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
04:52AM	Gilead signs agreements to facilitate access to HIV prevention drug (Pharmaceutical Technology)
Oct-02-24 10:43AM	Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries (PR Newswire)
08:30AM	Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries (Business Wire)
Oct-01-24 06:00PM	Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know (Zacks)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Dec 19 '24	Buy	21.37	940,499	20,098,464	2,209,471	Dec 23 08:26 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM
Dickinson Andrew D	Chief Financial Officer	Dec 16 '24	Sale	91.96	8,500	781,660	132,373	Dec 17 05:27 PM
ANDREW DICKINSON	Officer	Dec 16 '24	Proposed Sale	91.96	8,500	781,660		Dec 16 04:08 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Option Exercise	70.50	248,645	17,528,577	387,564	Dec 03 02:43 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Sale	92.76	248,645	23,065,271	138,919	Dec 03 02:43 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Option Exercise	62.44	145,413	9,079,689	245,012	Nov 29 08:10 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Sale	91.92	164,211	15,094,013	80,801	Nov 29 08:10 PM
ANDREW DICKINSON	Officer	Nov 29 '24	Proposed Sale	92.76	248,645	23,065,258		Nov 29 02:35 PM
Bluestone Jeffrey	Director	Nov 26 '24	Option Exercise	61.24	10,000	612,442	15,708	Nov 27 06:14 PM
Bluestone Jeffrey	Director	Nov 26 '24	Sale	91.39	6,788	620,356	8,920	Nov 27 06:14 PM
MERDAD V PARSEY	Officer	Nov 27 '24	Proposed Sale	91.92	164,211	15,094,008		Nov 27 04:15 PM
Bluestone Jeffrey	Director	Nov 26 '24	Proposed Sale	91.39	6,788	620,356		Nov 26 07:31 PM
Mercier Johanna	Chief Commercial Officer	Nov 06 '24	Sale	91.28	5,000	456,400	73,127	Nov 07 04:38 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Option Exercise	57.92	25,000	1,448,000	125,189	Nov 07 04:32 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Sale	91.50	25,590	2,341,485	99,599	Nov 07 04:32 PM
MERDAD V PARSEY	Officer	Nov 06 '24	Proposed Sale	91.50	25,590	2,341,485		Nov 06 04:19 PM
JOHANNA MERCIER	Officer	Nov 06 '24	Proposed Sale	91.28	5,000	456,400		Nov 06 04:07 PM
Parsey Merdad	Chief Medical Officer	Oct 01 '24	Sale	83.83	2,000	167,660	100,189	Oct 02 04:58 PM
MERDAD V PARSEY	Officer	Oct 01 '24	Proposed Sale	83.83	2,000	167,660		Oct 01 04:27 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Option Exercise	57.92	25,000	1,448,000	123,435	Sep 13 07:07 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Sale	84.50	21,246	1,795,287	102,189	Sep 13 07:07 PM
Mercier Johanna	Chief Commercial Officer	Sep 12 '24	Sale	83.78	29,357	2,459,577	78,127	Sep 13 05:08 PM
MERDAD V PARSEY	Officer	Sep 12 '24	Proposed Sale	84.50	21,246	1,795,287		Sep 12 04:45 PM
JOHANNA MERCIER	Officer	Sep 12 '24	Proposed Sale	83.78	29,357	2,459,577		Sep 12 04:43 PM
Mercier Johanna	Chief Commercial Officer	Aug 28 '24	Sale	78.03	9,513	742,299	105,466	Aug 29 03:23 PM
JOHANNA MERCIER	Officer	Aug 28 '24	Proposed Sale	78.03	9,513	742,299		Aug 28 04:18 PM
Mercier Johanna	Chief Commercial Officer	Aug 13 '24	Sale	73.98	5,490	406,150	114,979	Aug 14 02:23 PM
JOHANNA MERCIER	Officer	Aug 13 '24	Proposed Sale	73.98	5,490	406,150		Aug 13 04:27 PM
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380	Jul 01 08:06 PM
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706	Feb 29 06:35 PM
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936	Feb 29 06:35 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124	Jan 31 05:00 PM
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534	Jan 17 06:01 PM
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729	Jan 10 03:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience